[1]Ghatalia P,Je Y,Kaymakcalan MD,et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors[J]. Br J Cancer,2015,112(2):296-305.[2]Lipshultz SE,Cohen H,Colan SD,et al. The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity[J]. Leuk Lymphoma,2006,47(8):1454-1458.
[3]Babiker HM,McBride A,Newton M,et al. Cardiotoxic effects of chemotherapy:a review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system[J]. Crit Rev Oncol Hematol,2018,126:186-200.
[4]Thavendiranathan P,Abdel-Qadir H,Fischer HD,et al. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice:a population-based cohort study[J]. J Clin Oncol,2016,34(19):2239-2246.
[5]Hooning MJ,Botma A,Aleman BM,et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer[J]. J Natl Cancer Inst,2007,99(5):365-375.
[6]Bloom MW,Hamo CE,Cardinale D,et al. Cancer therapy-related cardiac dysfunction and heart failure:part 1:definitions,pathophysiology,risk factors,and imaging[J]. Circ Heart fail,2016,9(1):e002661.
[7]Tewey KM,Chen GL,Nelson EM,et al. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase Ⅱ[J]. J Biol Chem,1984,259(14):9182-9187.
[8]Nicolazzi MA,Carnicelli A,Fuorlo M,et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer[J]. Eur Rev Med Pharmacol Sci,2018,22(7):2175-2185.
[9]Geisberg CA,Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage[J]. Curr Hypertens Rep,2010,12(6):404-410.
[10]Grenier MA,Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults[J]. Semin Oncol,1998,25(4 suppl 10):72-85.
[11]Abu-Khalaf MM,Juneja V,Chung GG,et al. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A),paclitaxel (T),and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer[J]. Breast Cancer Res Treat,2007,104(3):341-349.
[12]Dolladille C,Akroun J,Morice PM,et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors:a safety meta-analysis[J]. Eur Heart J,2021,42(48):4964-4977.
[13]Ghidini M,Fusco N,Salati M,et al. The emergence of immune-checkpoint inhibitors in colorectal cancer therapy[J]. Curr Drug Targets,2021,22(9):1021-1033.
[14]Langford CA,Cuthbertson D,Ytterberg SR,et al. A randomized,double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis[J]. Arthritis Rheumatol,2017,69(4):837-845.
[15]Kamesh L,Heward JM,Williams JM,et al. CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis[J]. Rheumatology (Oxford),2009,48(12):1502-1505.
[16]周扬,刘宁波,黄飞,等. 人类表皮生长因子受体-2单链抗体抑制高表达人类表皮生长因子受体-2肿瘤生长[J]. 中华实验外科杂志,2017,34(7):1111-1114.
[17]Pondé NF,Lambertini M,de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity[J]. ESMO Open,2016,1(4):e000073.
[18]Hu Y,Sun B,Zhao B,et al. Cisplatin-induced cardiotoxicity with midrange ejection fraction:a case report and review of the literature[J]. Medicine (Baltimore),2018,97(52):e13807.
[19]Haugnes HS,Wethal T,Aass N,et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer:a 20-year follow-up study[J]. J Clin Oncol,2010,28(30):4649-4657.
[20]Latifi Y,Moccetti F,Wu M,et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib[J]. Blood,2019,133(14):1597-1606.
[21]Thursby E,Juge N. Introduction to the human gut microbiota[J]. Biochem J,2017,474(11):1823-1836.
[22]Zhou X,Li J,Guo J,et al. Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction[J]. Microbiome,2018,6(1):66.
[23]Lam V,Su J,Koprowski S,et al. Intestinal microbiota determine severity of myocardial infarction in rats[J]. FASEB J,2012,26(4):1727-1735.
[24]Fan Y,Pedersen O. Gut microbiota in human metabolic health and disease[J]. Nat Rev Microbiol,2021,19(1):55-71.
[25]Zabell A,Tang WH. Targeting the Microbiome in Heart Failure[J]. Curr Treat Options Cardiovasc Med,2017,19(4):27.
[26]Mamic P,Chaikijurajai T,Tang WHW. Gut microbiome—A potential mediator of pathogenesis in heart failure and its comorbidities:State-of-the-art review[J]. J Mol Cell Cardiol,2021,152:105-117.
[27]Lam V,Su J,Hsu A,et al. Intestinal microbial metabolites are linked to severity of myocardial infarction in rats[J]. PLoS One,2016,11(8):e0160840.
[28]Montassier E,Gastinne T,Vangay P,et al. Chemotherapy-driven dysbiosis in the intestinal microbiome[J]. Aliment Pharmacol Ther,2015,42(5):515-528.
[29]Touchefeu Y,Montassier E,Nieman K,et al. Systematic review:the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis—Current evidence and potential clinical applications[J]. Aliment Pharmacol Ther,2014,40(5):409-421.
[30]Shen S,Lim G,You Z,et al. Gut microbiota is critical for the induction of chemotherapy-induced pain[J]. Nat Neurosci,2017,20(9):1213-1216.
[31]Deleemans JM,Chleilat F,Reimer RA,et al. The chemo-gut study:investigating the long-term effects of chemotherapy on gut microbiota,metabolic,immune,psychological and cognitive parameters in young adult Cancer survivors;study protocol[J]. BMC Cancer,2019,19(1):1243.
[32]Huang K,Liu Y,Tang H,et al. Glabridin prevents doxorubicin-induced cardiotoxicity through gut microbiota modulation and colonic macrophage polarization in mice[J]. Front Pharmacol,2019,10:107.
[33]An L,Wuri J,Zheng Z,et al. Microbiota modulate Doxorubicin induced cardiotoxicity[J]. Eur J Pharm Sci,2021,166:105977.
[34]Meng C,Bai C,Brown TD,et al. Human gut microbiota and gastrointestinal cancer[J]. Genomics Proteomics Bioinformatics,2018,16(1):33-49.
[35]Sinha R,Ahn J,Sampson JN,et al. Fecal microbiota,fecal metabolome,and colorectal cancer interrelations[J]. PLoS One,2016,11(3):e152126.
[36]Tourelle KM,Boutin S,Weigand MA,et al. The association of gut microbiota and complications in gastrointestinal-cancer therapies[J]. Biomedicines,2021,9(10):1305.